Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity in Healthy Adult Males of a DNA Plasmid Vaccine for HS Avian Influenza (VGX-3400) Administered by Intramuscular (IM) Injection Followed by Electroporation (EP).
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2016
At a glance
- Drugs VGX 3400 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions
- 16 Mar 2015 Planned primary completion date changed from 1 Feb 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov record.
- 16 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Jul 2011 Pooled results from this and a parallel trial in the US have been presented at DNA Vaccines 2011, according to an Inovio Pharmaceuticals media release.